Albumin-based nanoplatforms hold immense promise for targeted drug delivery in triple-negative breast cancer (TNBC); however, their clinical translation is hampered by several critical challenges that must be addressed for improved therapeutic efficacy. Here, ALB is linked to triple-negative breast carcinoma.